已收盤 11-20 16:00:00 美东时间
-0.660
-0.15%
If you only skimmed headlines about Tavneos investigations and Prolia facing biosimilar pressure, Amgen might have looked like a minefield in early 2026. Investors who held Amgen from the start of the year are up 36.5%, including dividends. If you had been weighing those competing analyst views in January, how would you have judged whether pipeline momentum could outweigh regulatory risk and aging blockbusters long enough to earn that outcome? On
11-21 21:08
(来源:求实药社) 11月19日(今天),德国生物技术公司Disco Pharmaceuticals宣布,已与艾伯维(AbbVie)达成战略合作及许可选择权协议...
11-20 11:55
今日重点评级关注:摩根大通:维持Biohaven"超配"评级,目标价从14美元升至35美元;Craig-Hallum:维持红罗宾"买入"评级,目标价从14.5美元升至15.5美元
11-20 08:33
Piper Sandler analyst David Amsellem reiterates Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $457 to $542.
11-19 23:12
三大指数涨跌不一,纳指涨0.4%,道指跌1.1%;英伟达再跌近3%,创25年6月来新低;网安股走强,CrowdStrike涨近8%;光通信股普跌,AAOI跌近10%>>
11-19 06:47
11月19日,安进(AMGN)收跌3.07%,报443.89美元,成交额11.5亿美元,市值2401.05亿美元。 行情数据 • 开盘价:453.52美元 •...
11-19 05:31
ProKidney Corp. announced the promotion of Farah Ali, M.D., M.S., to Chief Medical Officer. Dr. Ali, a board-certified pediatric nephrologist with over a decade of experience in clinical development, will lead the company's pivotal Phase 3 PROACT 1 study of rilparencel, aiming to preserve kidney function in advanced CKD patients with type 2 diabetes. Her appointment reflects ProKidney's commitment to advancing innovative therapies for chronic kid...
11-18 21:15
NervGen appoints Dr. Sam Jackson as Chief Medical Officer to lead clinical development of NVG-291 for spinal cord injury and expand its pipeline. Dr. Jackson, with extensive experience in neuroscience trials, will oversee the Phase 3 RESTORE study and advance the therapy toward FDA approval. NVG-291 aims to counteract inhibitory effects of chondroitin sulfate proteoglycans, offering potential for nervous system repair.
11-18 12:15
最新披露的机构持仓数据显示,北方信托投资于最新季度调整了对安进(AMGN)的持仓。 主要变动如下: 持仓变化:减持-8.18万股 仓位变化幅度:-2.06%...
11-17 15:22
数据显示,VanEck Vectors 生物科技 ETF前十大重仓股合计占基金资产的73.1224%。 其中,第一大重仓股为安进,持仓占比16.7974%;第二...
11-17 07:01